1. Transcriptional reprogramming in neonatal hematopoietic stem and progenitor cells
- Author
-
Yanan Li and Jeffrey A. Magee
- Subjects
Cancer Research ,Transcription, Genetic ,Gene regulatory network ,Biology ,medicine.disease_cause ,Article ,Gene expression ,Genetics ,medicine ,Animals ,Humans ,Gene Regulatory Networks ,Cell Self Renewal ,Progenitor cell ,Molecular Biology ,Gene ,Mutation ,Leukemia ,Infant, Newborn ,Gene Expression Regulation, Developmental ,Cell Biology ,Hematology ,Hematopoietic Stem Cells ,Cell biology ,Haematopoiesis ,Stem cell ,Transcriptome ,Reprogramming - Abstract
Hematopoietic stem cells (HSCs) and lineage committed hematopoietic progenitor cells (HPCs) undergo profound shifts in gene expression during neonatal and juvenile stages of life. Temporal changes in HSC/HPC gene expression underlie concomitant changes in self-renewal capacity, lineage biases and hematopoietic output. Moreover, they can modify disease phenotypes. For example, childhood leukemias have distinct driver mutation profiles relative to adult leukemias, and they may arise from distinct cells of origin. The putative relationship between neonatal HSC/HPC ontogeny and childhood blood disorders highlights the importance of understanding how, at a mechanistic level, HSCs transition from fetal to adult transcriptional states. In this perspective piece, we summarize recent work showing that the transition is uncoordinated and imprecisely timed. We discuss implications of these findings, including mechanisms that might enable neonatal HSCs and HPCs to acquire adult-like properties over a drawn-out period of time, in lieu of precise gene regulatory networks. The transition from fetal to adult transcriptional programs coincides with a pulse of type I interferon signaling that activates many genes associated with the adult-like state. This pulse may sensitize HSCs/HPCs to mutations that drive leukemogenesis shortly after birth. If we can understand how developmental switches modulate HSC and HPC fate after birth – both under normal circumstances and in the setting of disease-causing mutations – we can potentially reprogram these switches to treat or prevent childhood leukemias.
- Published
- 2021
- Full Text
- View/download PDF